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Genome Editing, 
biochemical 
superpower?
by Freddie Theodoulou, Science Editor
“If you had a superpower, what would be?” a 
PhD student once asked me. After an evening 
fighting my way through the crowded London 
Underground having seen a kids’ fantasy film, 
I didn’t hesitate: “I’d like to be able to shoot bolts 
of lightning from the palms of my hands”. The 
student turned to my colleague and posed the 
same question. “I’d like the power to heal” he replied simply. Well that told 
me. But it’s an interesting question: if you had a biochemical superpower, 
what would it be? The ability to quantify all the transcripts in the genome? 
Sequence a genome in an afternoon? No problem! (provided your genome 
isn’t too large)   I’d quite like the ability to find substrates for all the enzymes of 
unknown function, though sadly that’s not quite possible yet. But how would 
you like to be able alter the genome at will? Courtesy of genome editing, what 
once seemed like fantasy is now reality.
Editing is not just a reality but a rapidly evolving field: would-be genome 
engineers have the choice of at least four different tools with which to re-
write genetic instructions in their organism of choice- zinc finger nucleases, 
meganucleases, TALENs or CRISPR. But it is CRISPR that has garnered most 
column inches in the academic and lay press alike. Unfortunately this owes as 
much to the fierce patent dispute currently raging between its inventors as to its 
power and relative simplicity. Such is its popularity that “CRISPR” has entered 
the vernacular as a verb- I’ve already lost count of the times I’ve heard “We’re 
going to CRISPR in this mutation/tag/gene” in seminars. Cynicism aside, this 
is understandable given the potentially exquisite specificity of the technique: 
changing a single amino acid can alter protein fate or function; changing a 
single base can alter a microRNA binding site or an epigenetic mark. All this, 
without the footprint of standard genetic modifications or the linkage problems 
and lack of precision associated with breeding by mutagenesis and selection.
This issue brings you a selection of thought-provoking features on 
genome editing, from the biology behind the technology to applications 
in agriculture and medicine, plus reflections on the legal and regulatory 
landscape. The diversity of potential outcomes and the precision of genome 
editing make a strong case for regulating genome-edited products, rather 
than the process itself, promising to bring applications to market faster than 
conventional genetically modified organisms, provided off-target effects 
can be avoided. Whilst the ethical ramifications of re-writing genomes 
have provoked anxiety, especially when it comes to human germline 
modification, approval has recently been granted to several teams seeking 
to perform embryo editing research. Helen Albert interviews Frederik 
Lanner, one of the scientists   with permission to take the first steps down 
this potentially life-transforming, but ethically complex route. We also hear 
from CRISPR pioneer Rodolphe Barrangou and Marco Weinberg, who is 
using the technology to target pathogenic viruses. Reflecting on their newly 
acquired superpowers, they may well be contemplating Ben Parker’s advice 
to Spiderman, “With great power comes great responsibility”.  ■
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